As more countries move towards elimination of malaria, natural immunity will decline and there will be an increasing need for new chemoprotective medicines to ensure populations remain malaria free.
Chemoprotective medicines would help in the control of potential malaria epidemics, and could be used to protect vulnerable populations such as pregnant women and children.
Developing long-acting injectable chemoprotective medicines
MMV is working with Janssen Pharmaceuticals to develop long-acting injectable chemoprotective medicines that could be administered monthly or even less frequently.
Read more in an interview with Dr Alfred Tonelli, Head of External Innovation, Johnson and Johnson Global Public Health